PRODUCT INFORMATION



ACE2 (human) Monoclonal Antibody - Biotinylated (Clone AC18F)

Item No. 30583

Overview and Properties

Contents: This vial contains 50 µg of protein G-purified monoclonal antibody. Synonyms: ACE-related Carboxypeptidase, ACEH, Angiotensin-converting Enzyme 2,

Angiotensin-converting Enzyme Homolog, Metalloprotease MPROT15

Immunogen: Recombinant human ACE2

Species Reactivity: (+) Human Form: Liquid

-20°C (as supplied); avoid freeze/thaw cycles Storage:

Stability:

Storage Buffer: 0.2 µm-filtered solution in PBS, pH 7.4


Concentration: 1 mg/ml Clone: AC18F Host: Mouse Isotype: IgG1ĸ

Applications: ELISA (direct or indirect), Flow Cytometry (FC), and Western blot (WB; using ECL);

the recommended starting dilution is 1:2,000-1:10,000 for ELISA and WB and 1:1,000 for FC. The suggested blocking and dilution buffer for WB is PBST with 0.05% Tween 20 and 5% skim milk. The suggested incubation time for WB is 1 hour at room temperature. Other applications were not tested, therefore optimal working

concentration/dilution should be determined empirically.


Images



Lane 1: MW Markers Lane 2: hACE2 (Fc protein)

Lane 3: hACE2 (Ecto domain) (FLAG®-tagged) Lane 4: Other hGITR (Fc protein) (control)

WB analysis using ACE2 (human) Monoclonal Antibody - Biotinylated (Clone AC18F) (Item No. 30583) at 1.2 000 dilution



FACS: HepG2 cells were stained ACE2 (human) Monoclonal Antibody - Biotinylated (Clone AC18F) (Item No. 30583).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 04/01/2021

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM

PRODUCT INFORMATION



Description

Angiotensin-converting enzyme 2 (ACE2) is a carboxypeptidase and homolog of ACE1 that is encoded by *ACE2* in humans.^{1,2} It is a type I transmembrane protein composed of a cytoplasmic tail and an extracellular domain containing an HEMGH motif, characteristic of zinc-metallopeptidases, which exhibits carboxymonopeptidase activity.¹ ACE2 is expressed in vascular endothelial cells where it catalyzes the conversion of angiotensin I to angiotensin 1-9, a peptide of unknown function, and angiotensin II to the vasodilatory peptide angiotensin 1-7 to regulate systemic blood pressure.^{1,2} It is also expressed in the epithelial cells of the kidney, heart, lung, small intestine, and liver and has roles in fluid homeostasis, cardiac contractility, and amino acid absorption, as well as the prevention of pulmonary fibrosis and hypertension. ACE2 also acts as a functional receptor for severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 to facilitate viral entry into host cells.^{3,4} Cayman's ACE2 (human) Monoclonal Antibody-Biotinylated (Clone AC18F) can be used for ELISA, flow cytometry (FC), and Western blot (WB) applications.

References

- 1. Perlot, T. and Penninger, J.M. ACE2 From the renin-angiotensin system to gut microbiota and malnutrition. *Microbes Infect.* **15(13)**, 866-873 (2013).
- 2. Santos, R.A.S., Sampaio, W.O., Alzamora, A.C., et al. The ACE2/angiotensin-(1-7)/MAS axis of the renin-angiotensin system: Focus on angiotensin-(1-7). Physiol. Rev. 98(1), 505-553 (2018).
- 3. Hoffmann, M., Kleine-Weber, H., Schroeder, S., et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by clinically proven protease inhibitor. *Cell* **181**, 1-10 (2020).
- 4. Gurwitz, D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev. Res. (2020).